Abstract
The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low-grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan-bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow-up of 23 months after the end of the bevacizumab-irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan-bevacizumab can improve progression-free survival in children with LGG.
Keywords:
Angiogenesis; cancer; children; low-grade glioma; malignancies metronomic chemotherapy.
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
MeSH terms
-
Administration, Metronomic
-
Adolescent
-
Antineoplastic Agents, Phytogenic / administration & dosage*
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / administration & dosage
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Child
-
Combined Modality Therapy
-
Disease Progression
-
Female
-
Glioma / diagnostic imaging
-
Glioma / drug therapy*
-
Glioma / pathology*
-
Humans
-
Irinotecan
-
Maintenance Chemotherapy
-
Male
-
Neoplasm Grading
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local
-
Retreatment
-
Retrospective Studies
-
Vinblastine / administration & dosage*
-
Vinblastine / adverse effects
Substances
-
Antineoplastic Agents, Phytogenic
-
Bevacizumab
-
Vinblastine
-
Irinotecan
-
Camptothecin